Inovio Pharmaceuticals, Inc.
(NYSE MKT: INO) announced today that preliminary results of a phase II
clinical trial to treat leukemia with a WT1 DNA vaccine delivered with
Inovio's proprietary electroporation delivery system showed robust
vaccine-specific antibody responses in all vaccinated subjects evaluated to
date. Furthermore, T cell immune responses, including those of the "killer T
cells," were detected. Antibody and T cell responses are strong signals of the
DNA vaccine's potential to treat the disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in